Survival outcomes according to tumor stage confirmed significant differences between the two groups of GSN expression (p = 0.021 for stage II patients; p = 0.027 for stage III patients), and showed a trend toward better survival rates in the OAS2 overexpression group than in the underexpression group. This evidence concerns the gene OAS2 and neoplasm.